Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Omnicell Inc.

Piper Sandler analyst Jessica Tassan maintained a Buy rating on Omnicell today and set a price target of $63.00. According to TipRanks, Tassan is a...

Omnicell (OMCL) Gets a Buy from Piper Sandler

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genmab (GMAB – Research Report), Omnicell (OMCL – Re...

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Omnicell (OMCL) and Syndax Pharmaceuticals (SNDX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Omnicell (OMCL – Research Report) and Butterfly Netw...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OMCL	$45.57	-0.28%	490.21K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OMCL	$45.57	-0.3%	490.21K
3
4
5
6

OMCL

OMCL

Get Omnicell Inc. Data in Excel

Get Omnicell Inc. Data in Excel